Skip to main content
Fig. 2 | Journal of Innovation and Entrepreneurship

Fig. 2

From: A novel valuation model for medical intervention development based on progressive dynamic changes that integrates Health Technology Assessment outcomes with early-stage innovation and indication-specific clinical success rates

Fig. 2

Clinical trial rates for CVD vs generic ROI: Phase III clinical trial success rates have increased, but this has not been reflected in the ROI. Data for CVD success rates from 2010 to 2015 were obtained from Wong et al. (2018) and plotted against industry wide ROI on R&D figures obtained from Deloitte

Back to article page